News

Flu jabs halve threat of embolism in under-50s

12-Nov-08

Having a flu jab could almost halve the risk of developing venous thromboembolisms (VTE) among the under 50s, according to French research.

The findings, presented at the annual AHA scientific sessions are the first to show that influenza vaccination can offer protection against VTEs, such as DVT and pulmonary embolism.

The study compared 727 people with a history of VTE with 727 others, matched for age and sex, who had not suffered a VTE.

The participants completed a questionnaire to identify whether they had been vaccinated against influenza in the previous 12 months and to identify other risk factors for VTE, like the use of oral contraceptives, frequency of long distance travel and family history of thrombotic disease.

Overall, the researchers found that among those who had received a flu jab, the risk of developing VTE fell by 26 per cent.

But the benefits of having a flu jab were found to be more pronounced in younger people. Having a flu jab reduced the risk of VTE by 48 per cent in those below theage of 52.

Lead researcher Dr Joseph Emmerich, from the University Paris Descartes, proposed that systemic inflammatory reactions to infectious agents could trigger a thrombotic process.

sanjay.tanday@haymarket.com

Comment below and tell us what you think

Comments

Only registered users may comment. Log in now or register for a free account.

There are problems with your form submission.

Please review the errors shown below.



Forgot your password?

Quick search - use * for an abbreviated search, eg nico*

 
 

Healthcare Republic Forums

 

Jobs

 

Job of the Week

Latest Clinical Articles

Abnormal uterine bleeding

Contributed by Mr Antonio V Antoniou, consultant gynaecologist and lead in minimal access surgery an... Read more

Chronic low back pain

Dr Mark Ritchie, GPSI in pain management, Morriston, Swansea Read more

Acute and sub-acute back pain

Contributed by Dr Mark Ritchie, GPSI in pain management, Morriston, Swansea Read more

Show all clinical articles

MIMS Product News

New drug - Stelara

Janssen-Cilag has launched Stelara for the treatment of moderate to severe plaque psoriasis where ot... Read more

New high-strength nicotine patch

Nicorette Invisipatch is the latest addition to the range of available nicotine replacement therapy ... Read more

Prolonged-release aspirin

Flamasacard, a prolonged-release formulation of aspirin, for secondary prophylaxis after a first cor... Read more